Search Results
Apr 29, 2026, 09:00 ET Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
ALLELE study, made it unlikely that the FDA would approve the tabelecleucel BLA; (ii) accordingly, tabelecleucel's regulatory prospects were overstated; (iii) the aforementioned manufacturing issues also subjected Atara to a heightened risk of regulatory scrutiny, as well as jeopardized its ongoing clinical
More news about: Levi & Korsinsky
Apr 29, 2026, 09:00 ET RGC LAWSUIT ALERT: Levi & Korsinsky Notifies Regencell Bioscience Holdings Limited Investors of a Class Action Lawsuit and Upcoming Deadline
manipulation; (ii) the resulting volatility in the market for the Company's ordinary shares exposed Regencell's investors to significant financial risk; (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant
More news about: Levi & Korsinsky, LLP
Apr 29, 2026, 09:00 ET Corsha Awarded $50 Million Sole-Source IDIQ by the Defense Logistics Agency (DLA) to Deliver Zero Trust Connectivity Across Critical Operational Systems
track record across the DoW, including an active Authority to Operate (ATO) and deployments with the U.S. Air Force and DLA, and multiple SBIR and Phase III awards across the Armed Forces. As industrial enterprises face growing demand to connect operational systems with modern applications, and adversaries
More news about: Corsha
Apr 29, 2026, 08:30 ET WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
operations, and more efficient manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.WuXi Biologics regards
More news about: WuXi Biologics
Apr 29, 2026, 08:00 ET Citius Oncology Ships First International Order of LYMPHIR™ to Europe
clinical practice.LYMPHIR was approved by the U.S. Food and Drug Administration in August 2024 for the treatment of adult patients with Stage I–III relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy, and was commercially launched in the United States
More news about: Citius Oncology, Inc.
Apr 29, 2026, 08:00 ET Sadis & Goldberg LLP Announces Pendency and Proposed Settlement of Class Action Involving E-Commerce China Dangdang Inc. American Depositary Share Holders
Arbitration with prejudice as provided in the Stipulation and Agreement of Settlement, dated as of February 13, 2026, as amended on April 10, 2026; (iii) approve the proposed Plan of Allocation for distribution of the proceeds of the Settlement (the "Net Settlement Fund") to Settlement Class Members;
More news about: Sadis & Goldberg LLP
Apr 29, 2026, 08:00 ET Perimeter Showcases Claire™ for Intraoperative Breast Cancer Margin Assessment at ASBrS 2026
material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include,
More news about: Perimeter Medical Imaging AI Inc.
Apr 29, 2026, 08:00 ET Beasley Broadcast Group Announces Expiration of Exchange Offer, Tender Offer and Consent Solicitations and Receipt of Valid Consents from 100% of Outstanding Existing First Lien Noteholders to Proposed Amendments to Existing First Lien Notes Indenture and Acceptance of 99.53% of Outstanding Existing Second Lien Notes
Lien Notes" and, together with the Existing Second Lien Notes, the "Existing Notes") at a purchase price of 100% (the "Tender Offer") and (iii) the solicitation of consents (the "Consent Solicitations") of the terms and conditions set forth in the Confidential Offering Memorandum and Solicitation
More news about: Beasley Media Group, Inc.
Apr 29, 2026, 07:42 ET ADAMA Reports First Quarter 2026 Results
acquisition; (ii) non-cash amortization net charges related to intangible assets created as part of the Purchase Price Allocation (PPA) on acquisitions; (iii) capital gain from sale of a subsidiary's logistics center in Israel; and (iv) restructuring costs which significantly decreased as part of the implementation
More news about: ADAMA Ltd.
Apr 29, 2026, 07:39 ET First Mining Provides Update at Pickle Crow Gold Project
to, statements with respect to: (i) disclosure by Bellavista; (iI) the Company's plans with respect to advancing its portfolio of gold projects; and (iii) feasibility and permitting activities related to the Springpole Gold Project. Forward-looking statements reflect the beliefs, opinions
More news about: First Mining Gold Corp.
Apr 29, 2026, 07:30 ET NAPCO Security Technologies to Announce Fiscal Third Quarter 2026 Results Monday, May 4, 2026
the Company undertakes no duty to update such information, except as required under applicable law. Contact: Francis J. Okoniewski IIIVice President of Investor Relations NAPCO Security Technologies, Inc. 800-645-9445 x 374 Mobile: 516-404-3597
More news about: NAPCO Security Technologies, Inc.
Apr 29, 2026, 07:00 ET NORTHSTAR REPORTS 2025 YEAR END FINANCIAL AND OPERATING RESULTS
plans for its inaugural commercial facility in Calgary; (ii) the Company's strategic priorities, development plans and expected future activities; and (iii) the Company's ability to execute its business plans. Such statements are subject to risks and uncertainties that may cause actual results, performance
More news about: Northstar Clean Technologies Inc.
Apr 29, 2026, 06:52 ET JinkoSolar Announces First Quarter 2026 Financial Results
fair value of convertible notes issued by Jinko Solar Co., Ltd. ("Jiangxi Jinko") in 2023, (ii) the change in fair value of long-term investment, and (iii) share-based compensation expenses, compared with adjusted net loss attributable to JinkoSolar Holding Co., Ltd.'s ordinary shareholders of RMB837.7
More news about: JinkoSolar Holding Co., Ltd.
Apr 29, 2026, 06:05 ET Avantor® Reports First Quarter 2026 Results
loss adjusted for the following items: (i) amortization of acquired intangible assets, (ii) charges associated with the impairment of certain assets, (iii) gain on sale of business, and (iv) certain other adjustments. Adjusted Operating Income margin is Adjusted Operating Income divided by net sales as
More news about: Avantor and Financial News
Apr 29, 2026, 06:00 ET Stanley Black & Decker Reports Strong 1Q 2026 Results
availability and prices, inflation and deflation, interest rate volatility, currency exchange rates, and uncertainties in the global financial markets; (iii) laws, regulations and governmental policies affecting the Company's activities in the countries where it does business or sources supply inputs, including
More news about: Stanley Black & Decker, Inc.
Apr 29, 2026, 05:22 ET Energenesis Biomedical to Present Clinical Application of ENERGI-F703DFU for Diabetic Foot Ulcers at EWMA 2026
the wound site to promote cell regeneration and activate intrinsic repair mechanisms.ENERGI-F703DFU is currently enrolling patients in a Phase III clinical trial (NCT05930210) in Taiwan and the United States. The study targets ulcers classified as Grade 1 to Grade 2 per the Wagner Grading System,
More news about: Energenesis Biomedical Co., Ltd.
Apr 29, 2026, 03:47 ET Le premier nouveau médicament au monde à base de toxine botulique recombinante de type A a reçu l'autorisation de mise sur le marché en Chine : une révolution technologique lancée par Claruvis Pharmaceutical
bactérie Clostridium botulinum, et fournit une toxine d'une grande pureté et d'une activité spécifique élevée.Dans un essai clinique pivot de phase III multicentrique, randomisé, en double aveugle, contrôlé par placebo et traitement actif, mené en Chine, Retoxin® a satisfait à tous les critères
More news about: Claruvis Pharmaceutical
Apr 29, 2026, 03:45 ET Claruvis Pharmaceutical anuncia la aprobación de su fármaco recombinante de toxina botulínica tipo A
derivada de Clostridium botulinum, y proporciona una toxina con alta pureza y alta actividad específica.En un ensayo clínico multicéntrico de fase III, aleatorizado, doble ciego, controlado con placebo y con comparador activo, realizado en China, Retoxin® cumplió con todos los objetivos primarios
More news about: Claruvis Pharmaceutical
Apr 28, 2026, 21:00 ET Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study
exposure and optimizing the benefit–risk profile. In parallel, we continue to advance the oral Rentosertib program and remain on track to initiate Phase III trials in the second half of this year."Administration by inhalation is a complex drug delivery technology that requires combining formulation
More news about: Insilico Medicine
Apr 28, 2026, 19:12 ET Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
The findings of this pivotal phase III study are included in the Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), submitted to
More news about: Vanda Pharmaceuticals Inc.
Apr 28, 2026, 18:27 ET Bitmine Immersion Technologies (BMNR) gibt bekannt, dass seine ETH-Bestände einen beispiellosen Weltrekord von 5,078 Millionen Token erreicht haben und sich die gesamten Krypto- und Barbestände auf 13,3 Milliarden US-Dollar belaufen
wird weiterhin von einer Gruppe führender institutioneller Investoren unterstützt, darunter Cathie Wood von ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital und der Privatinvestor Thomas „Tom" Lee, um das Ziel von Bitmine zu unterstützen, 5 % der ETH zu erwerben
More news about: Bitmine Immersion Technologies, Inc.
Apr 28, 2026, 17:00 ET PROLOGIS DECLARES QUARTERLY DIVIDEND
local economic and political climates and conditions; (ii) changes in global financial markets, interest rates and foreign currency exchange rates; (iii) increased or unanticipated competition for our properties; (iv) risks associated with acquisitions, dispositions and development of properties, including
More news about: Prologis, Inc.
Apr 28, 2026, 16:40 ET Stoneridge's MirrorEye® Camera Monitor System Continues Strong Momentum, Achieving Record Global Sales and Production Milestones
respect to, among other things, our (i) future product and facility expansion, (ii) strategic focus following the sale of the Control Devices segment, (iii) acquisition strategy, (iv) investments and new product development, (v) growth opportunities related to awarded business, and (vi) operational expectations.
More news about: Stoneridge, Inc.
Apr 28, 2026, 16:30 ET Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results
In 2025, we achieved several regulatory milestones, including the approval of two National Category I New Veterinary Drugs and one National Category III New Veterinary Drug from the Ministry of Agriculture and Rural Affairs. We also secured new product approvals across multiple animal species, including
More news about: Zhengye Biotechnology Holding Limited
Apr 28, 2026, 16:19 ET ELS Declares Second Quarter 2026 Dividend
are not limited to the following: (i) the mix of site usage within the portfolio; (ii) yield management on our short-term resort and marina sites; (iii) scheduled or implemented rate increases on community, resort and marina sites; (iv) scheduled or implemented rate increases in annual payments under
More news about: Equity Lifestyle Properties, Inc.